varenicline

AssetAlso Varenicline Tartrate Nasal Spray, OC-01, varenicline solution, CP-526,555

Partial agonist of alpha-4 beta-2 nicotinic acetylcholine receptors.

Stage: Approved
Modality: Small molecule
Target: CHRNA4; 6
Indications: 174
Trials: 3
Developers

Indications

6

Smoking
Approved, accessdata.fda.gov, 7 Oct 2026
Smoking cessation
Approved, ema.europa.eu, 7 Oct 2026
Tobacco use cessation
Approved, ema.europa.eu, 7 Oct 2026

3 more

In the full profile

Targets and what it contains3
Owner and partners3
Trials174
Evidence for its targets3
Competitors12
Aging relevance1
Signals6

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 13 sources